拉米夫定联合胸腺素α1治疗乙型重型肝炎的临床观察  

The Effect of lamivudine combined with thymosin-α_1 in the treatment of patients with severe hepatitis B

作　　者：王堂明 李玉龙[1] 邱波[1] 李树民[1] 王云[1] 张雪梅[1] 邹荣[1] 

机构地区：[1]四川省攀枝花市第四人民医院(传染病医院)肝病科,617061

出　　处：《实用肝脏病杂志》2007年第2期94-95,101,共3页Journal of Practical Hepatology

基　　金：攀枝花市科学技术局科研资助项目(攀科成鉴字2006第21号)

摘　　要：目的观察拉米夫定联合胸腺素α1治疗乙型重型肝炎的疗效。方法选择乙型重型肝炎患者88例,治疗组44例用拉米夫定联合胸腺素α1治疗,对照组44例不作任何抗病毒及免疫调节剂治疗,两组均常规使用护肝、对症治疗。结果治疗组生存率为81.82%,与对照组生存率54.55%比较,经统计学处理有显著性差异(P<0.01)。结论拉米夫定联合胸腺素α1治疗乙型重型肝炎可明显降低死亡率,提高生存率,改善预后,值得临床进一步研究。Objective To explore the effect of/amivudine combined with thymosin-α1 in treatment of patients with severe hepatitis B. Methods 88 patients with severe hepatitis B were selected and forty-four patients received the treatment of lamivudine combined with thymosin-α1, while other forty-four received conventional therapy. Result The survival rate in lamivudine combined with thymosin-α1 group was 81.82 %, much higher than in conventional group （54.55 %, P 〈0. 01）. Conclusion Lamivudine combined with thymosin-α1 in treatment of patients with severe hepatitis B can effectively decrease mortality rate and increase the survival rate.

关 键 词：乙型重型肝炎 拉米夫定 胸腺素Α1 生存率 

分 类 号：R512.62[医药卫生—内科学]